SyntekaBio

SyntekaBio Capital Intensity

The Capital Intensity Ratio of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 1,357.00 %. In the previous year, Capital Intensity Ratio was 36,161.81 % — a change of -96.25% (lower).

Capital Intensity

1,357.00 %

YoY

-96.25%

Last updated:

Capital Intensity Ratio of SyntekaBio is 2025 1,357.00 % . Capital Intensity Ratio of SyntekaBio was 2024 36,161.81 % . It decreases by -96.25% lower compared to the previous year.

The SyntekaBio Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
4,224.88 KRW
Jan 1, 2019
10,392.06 KRW
Jan 1, 2020
7,344.53 KRW
Jan 1, 2021
21,436.07 KRW
Jan 1, 2022
22,824.03 KRW
Jan 1, 2023
42,880.19 KRW
Jan 1, 2024
36,161.81 KRW
Jan 1, 2025
1,357.00 KRW
The SyntekaBio Capital Intensity history
YEARCapital IntensityYoY
1,357.00 %-96.25%
36,161.81 %-15.67%
42,880.19 %+87.87%
22,824.03 %+6.47%
21,436.07 %+191.86%
7,344.53 %-29.33%
10,392.06 %+145.97%
4,224.88 %-26.61%
5,756.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Capital Intensity Ratio of SyntekaBio is 1,357.00 % in 2025.

Capital Intensity Ratio of SyntekaBio changed from 36,161.81 % to 1,357.00 %, representing a -96.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SyntekaBio

All Key Metrics — SyntekaBio